Tumor burden influences exposure and response to rituximab: Pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

Blood

Volumn 113, Issue 16, 2009, Pages 3765-3772

  Daydé, David ^a,b   Ternant, David ^a,b   Ohresser, Marc ^a,b   Lerondel, Stéphanie ^b   Pesnel, Sabrina ^b   Watier, Hervé ^a,b,c   Le Pape, Alain ^b,d   Bardos, Pierre ^a,b,c   Paintaud, Gilles ^a,b,c   Cartron, Guillaume ^d,e  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d INSERM   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENTARY DNA; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN TECHNETIUM 99 M; LUCIFERASE; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; C57BL 6 MOUSE; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG INFUSION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; IN VIVO STUDY; LYMPHOMA CELL; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMID; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; ISOGRAFT; LUMINESCENCE; LYMPHOMA; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; LYMPHOMA; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, ISOGENEIC; TUMOR BURDEN;

EID: 65549100701     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-175125     Document Type: Article

References (24)

1. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;98:754-758.
2. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
3. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006;12:4027-4035. (Pubitemid 44078090)
4. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507-2513. (Pubitemid 36857605)
5. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103-1108.
6. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95:3052-3056.
7. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833. (Pubitemid 28363048)
9. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol. 2002;13:928-943. (Pubitemid 34752689)
10. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma: the IDEC-C2B8 Study Group. Ann Oncol. 1998;9:527-534. (Pubitemid 28270641)
11. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005;23:1096-1102. (Pubitemid 46202264)
12. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 2007;62:43-52.
13. Mangel J, Buckstein R, Imrie K, et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as "in vivo purge" and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol. 2003;14:758-765.
14. Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun. 2008;29:521-526. (Pubitemid 351643419)
15. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171:1581-1587. (Pubitemid 36900094)
16. Shibata M, Hariya T, Hatao M, Ashikaga T, Ichikawa H. Quantitative polymerase chain reaction using an external control mRNA for determination of gene expression in a heterogeneous cell population. Toxicol Sci. 1999;49:290-296. (Pubitemid 29300415)
17. Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169-174. (Pubitemid 44314944)
18. Blasco H, Lalmanach G, Godat E, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods. 2007;325:127-139. (Pubitemid 47243660)
19. Maloney DG. Follicular NHL: From antibodies and vaccines to graft-versus-lymphoma effects. Hematology Am Soc Hematol Educ Program. 2007:226-232.
20. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood. 1994;83:1165-1173.
21. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
22. Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005;27:785-792. (Pubitemid 44391736)
23. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446.
24. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101:949-954.